| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Laboratory of Biological Chemistry and 2 Department of Ophthalmology, Medical School, University of Ioannina, Ioannina, Greece; 3 Department of Molecular Biology, University of Siena, Siena, Italy; and 4 Foundation of Research and Technology-Hellas, Biomedical Research Institute, Ioannina, Greece
In an attempt to identify phytochemicals contributing to the well-documented preventive effect of plant-based diets on cancer incidence and mortality, we have previously shown that certain flavonoids inhibit in vitro angiogenesis. Here, we show that the flavonoid luteolin inhibited tumor growth and angiogenesis in a murine xenograft model. Furthermore, luteolin inhibited vascular endothelial growth factor (VEGF)-induced in vivo angiogenesis in the rabbit corneal assay. In agreement, luteolin inhibited both VEGF-induced survival and proliferation of human umbilical vein endothelial cells (HUVECs) with an IC50 of about 5 µmol/L. Luteolin inhibited VEGF-induced phosphatidylinositol 3'-kinase (PI3K) activity in HUVECs, and this inhibition was critical for both the antisurvival and antimitotic affects of the compound. Indeed, luteolin abolished VEGF-induced activation of Akt, a downstream target of PI3K conveying both survival and mitotic downstream signals. Because overexpression of a constitutively active form of Akt rescued HUVECs only from the antisurvival effects of luteolin, the result indicated that luteolin targeted mainly the survival signals of the PI3K/Akt pathway. With regard to its antimitotic activity, luteolin inhibited VEGF-induced phosphorylation of p70 S6 kinase (S6K), a downstream effector of PI3K responsible for G1 progression. Indeed, VEGF-induced proliferation of HUVECs was sensitive to rapamycin, an inhibitor of p70 S6K activation. Surprisingly, luteolin did not affect VEGF-induced phosphorylation of extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases, a pathway that is considered important for the mitotic effects of VEGF. Thus, blockade of PI3K by luteolin was responsible for the inhibitory effects of the compound on VEGF-induced survival and proliferation of HUVECs. The antisurvival effects of luteolin were mediated via blockage of PI3K/Akt-dependent pathways, whereas inhibition of the PI3K/p70 S6K pathway mediated the antimitotic effects of the compound.
This article has been cited by other articles:
![]() |
C.-H. Tsai, F.-M. Lin, Y.-C. Yang, M.-T. Lee, T.-L. Cha, G.-J. Wu, S.-C. Hsieh, and P.-W. Hsiao Herbal Extract of Wedelia chinensis Attenuates Androgen Receptor Activity and Orthotopic Growth of Prostate Cancer in Nude Mice Clin. Cancer Res., September 1, 2009; 15(17): 5435 - 5444. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.R.M. R. Amin, O. Kucuk, F. R. Khuri, and D. M. Shin Perspectives for Cancer Prevention With Natural Compounds J. Clin. Oncol., June 1, 2009; 27(16): 2712 - 2725. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lamy, V. Bedard, D. Labbe, H. Sartelet, C. Barthomeuf, D. Gingras, and R. Beliveau The Dietary Flavones Apigenin and Luteolin Impair Smooth Muscle Cell Migration and VEGF Expression through Inhibition of PDGFR-{beta} Phosphorylation Cancer Prevention Research, November 1, 2008; 1(6): 452 - 459. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Albini, D. M. Noonan, and N. Ferrari Molecular Pathways for Cancer Angioprevention Clin. Cancer Res., August 1, 2007; 13(15): 4320 - 4325. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-T. Chiang, T.-D. Way, and J.-K. Lin Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21WAF1/CIP1 expression with rapamycin Mol. Cancer Ther., July 1, 2007; 6(7): 2127 - 2138. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Ju, X. Wang, H. Shi, W. Chen, S. A. Belinsky, and Y. Lin A Critical Role of Luteolin-Induced Reactive Oxygen Species in Blockage of Tumor Necrosis Factor-Activated Nuclear Factor-{kappa}B Pathway and Sensitization of Apoptosis in Lung Cancer Cells Mol. Pharmacol., May 1, 2007; 71(5): 1381 - 1388. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Shi, Q. Huang, X. Zhu, Y.-B. Ong, B. Zhao, J. Lu, C.-N. Ong, and H.-M. Shen Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization Mol. Cancer Ther., April 1, 2007; 6(4): 1338 - 1347. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. McCarty and K. I. Block Toward a Core Nutraceutical Program for Cancer Management Integr Cancer Ther, June 1, 2006; 5(2): 150 - 171. [Abstract] [PDF] |
||||
![]() |
K. Selvendiran, H. Koga, T. Ueno, T. Yoshida, M. Maeyama, T. Torimura, H. Yano, M. Kojiro, and M. Sata Luteolin Promotes Degradation in Signal Transducer and Activator of Transcription 3 in Human Hepatoma Cells: An Implication for the Antitumor Potential of Flavonoids. Cancer Res., May 1, 2006; 66(9): 4826 - 4834. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.-X. Shi, C.-N. Ong, and H.-M. Shen Protein Kinase C Inhibition and X-Linked Inhibitor of Apoptosis Protein Degradation Contribute to the Sensitization Effect of Luteolin on Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Cancer Cells Cancer Res., September 1, 2005; 65(17): 7815 - 7823. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |